John Shaughnessy Jr
Overview
Explore the profile of John Shaughnessy Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith R, et al.
Blood Adv
. 2025 Jan;
9(4):950-953.
PMID: 39786380
No abstract available.
2.
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, et al.
Am J Hematol
. 2024 Aug;
99(11):2222-2224.
PMID: 39109821
No abstract available.
3.
Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy Jr J, Zhan F, et al.
JAMA Netw Open
. 2022 Aug;
5(8):e2228877.
PMID: 36018590
Importance: The use of chimeric antigen receptor-T cell (CAR-T) therapy and bispecific antibodies in multiple myeloma is expanding, with encouraging early results. It is unknown if the current geographic distribution...
4.
Schinke C, Bird J, Qu P, Yaccoby S, Lyzogubov V, Shelton R, et al.
Curr Res Transl Med
. 2021 Apr;
69(3):103290.
PMID: 33894670
Epigenetic deregulation is increasingly recognized as a contributing pathological factor in multiple myeloma (MM). In particular tri-methylation of H3 lysine 27 (H3K27me3), which is catalyzed by PHD finger protein 19...
5.
Moreno-Bost A, Szmania S, Stone K, Garg T, Hoerring A, Szymonifka J, et al.
Cytotherapy
. 2010 Dec;
13(5):618-28.
PMID: 21171821
Background Aims: Immunotherapy targeting MAGE-A3 in multiple myeloma (MM) could eradicate highly aggressive and proliferative clonal cell populations responsible for relapse. However, expression of many cancer-testis antigens, including MAGE-A3, can...
6.
Dib A, Peterson T, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, et al.
Cell Div
. 2006 Oct;
1:23.
PMID: 17049078
Background: A high proliferative capacity of tumor cells usually is associated with shortened patient survival. Disruption of the RB pathway, which is critically involved in regulating the G1 to S...
7.
Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy Jr J, Yaccoby S
Br J Haematol
. 2006 Mar;
133(1):83-92.
PMID: 16512833
The microenvironment plays a critical role in facilitating cancer progression and metastasis. We previously demonstrated the ability of osteoclasts to support primary myeloma plasma cell (MM PC) growth. Our study...
8.
Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I, et al.
Oncogene
. 2005 Jul;
24(46):6936-44.
PMID: 16044163
ARK5, AMP-activated protein kinase (AMPK)-related protein kinase mediating Akt signals, is closely involved in tumor progression, and its stage-associated expression was observed in colorectal cancer. In this study, we found...
9.
Shaughnessy Jr J, Zhan F, Barlogie B, Stewart A
Best Pract Res Clin Haematol
. 2005 Jul;
18(4):537-52.
PMID: 16026736
Gene expression profiling is a powerful tool through which the biology of multiple myeloma can be dissected. We will describe in this chapter how early studies using this technology have...
10.
Qiang Y, Walsh K, Yao L, Kedei N, Blumberg P, Rubin J, et al.
Blood
. 2005 May;
106(5):1786-93.
PMID: 15886323
Multiple myeloma is an incurable form of lymphoid cancer characterized by accumulation of neoplastic plasma cells in the bone marrow cavity. Little is known about the mechanisms regulating myeloma cell...